Navigation Links
Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
Date:9/24/2010

et and down-modulates the PI3K/Akt pathway. Together, the PK and PD data demonstrate that CX-4945 is achieving pharmacologically active levels in plasma and in tumor cells and elicits a clear pharmacodynamic response.

"Clinical advancement of our first-in-class CK2 inhibitor, CX-4945, in patients with multiple myeloma represents another major milestone for Cylene. Moreover, the accompanying financing enables us to support the clinical trials and the expansion of our pipeline with high quality candidates emerging from our internal drug discovery platform.  The financing also illustrates the enthusiasm our investors have for CX-4945 and our highly original drug discovery platform," said Dr. William G. Rice, President and CEO of Cylene Pharmaceuticals.

"Our firm invests in companies that have the potential to lead innovations critical to the needs of patients, possess strong management expertise, perform novel proprietary science coupled with a mechanistic understanding of target diseases, and are capital-efficient with the potential to deliver substantial returns to shareholders. Cylene certainly fits these parameters," said Dr. Reinhard Ambros, Executive Director of the Novartis Venture Funds and Director of Cylene.  "Cylene's clinical development efforts, led by Dr. Daniel Von Hoff, lead the industry in targeting CK2 with potent and selective inhibitors for the treatment of various forms of cancer. This combination of features makes Cylene an attractive and exciting investment."

About Cylene Pharmaceuticals

Cylene Pharmaceuticals, Inc. is a San Diego-based, private biotechnology company discovering and developing targeted small molecule drugs to treat life-threatening cancers. Cylene's drug discovery platform, STAND (Selective TArgeting of Non-Oncogene Networks in Disease), has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the su
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
11. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... NEW YORK , Aug. 21, 2014 /PRNewswire/ ... OTCM) congratulates Immune Pharmaceuticals Inc., a biotechnology company, ... Capital Market.  Immune previously traded on OTCQX®, the ... operated by OTC Markets Group. Logo - ... Immune Pharmaceuticals on the successful execution of its ...
(Date:8/21/2014)... Aug. 21, 2014  Four-dimensional (4-D) printing develops ... on external stimuli such as changes in temperature. ... disruptive effect in multiple industries.  In the near ... by printing objects ranging from human organs to ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... Sofia, Bulgaria (PRWEB) August 21, 2014 ... was released today by Ontotext . Now ... and semantic analysis of structured and unstructured data is ... of the cost of enterprise technology. Organizations that do ... approaches for data management can use S4 since there ...
(Date:8/21/2014)... MA (PRWEB) August 21, 2014 ... company, has been recognized as one of the ... | 5000 magazine for the 2nd consecutive year. ... its 33rd annual Inc. 500|5000, an exclusive ranking ... represents the most comprehensive look at the most ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... ... awards program. In keeping with extensions given in previous years, the 2010 extended deadline is ... Needham, MA ... Best Practices awards program. In keeping with extensions given in previous years, the 2010 extended ...
... , WASHINGTON , Jan. 22 The ... hold a conference call hosted by Robert W. Musslewhite , Chief ... discuss the Company,s financial results for the quarter ended December 31, ... 2010 , at 6:00 p.m., Eastern Time .  The Company plans ...
... , EATONTOWN, N.J. , Jan. 22 ... field of biologic products for regenerative healing, announced today that its ... is designed to discourage coercive or unfair takeover tactics and to ... in the event that an unsolicited offer is made to acquire ...
Cached Biology Technology:The 2010 Bio-IT World Best Practices Deadline Has Been Extended 2The 2010 Bio-IT World Best Practices Deadline Has Been Extended 3The Advisory Board Company Schedules Third Quarter Conference Call for February 4, 2010 2Osteotech, Inc. Adopts Stockholder Rights Plan 2Osteotech, Inc. Adopts Stockholder Rights Plan 3
(Date:8/22/2014)... Anyone who has suffered an injury can probably remember ... signs that the body is fighting back against the ... programs are activated to aid in tissue regeneration. An ... repair and regeneration, helping the body to heal after ... mechanism may interfere with healing in situations in which ...
(Date:8/22/2014)... strong antioxidants and can reduce free radical ... against oxidative stress? Jianbo Zhao and co-workers ... Medical University, China discovered that green tea ... neuronal apoptosis, indicating green tea polyphenols play ... under oxidative stress. The relevant study has ...
(Date:8/21/2014)... team of scientists including researchers from the University of Georgia ... as canolain the journal Science . Their discovery paves ... used widely in farming and industry. , Canola is ... the winter crop is increasingly cultivated in Georgia. Canola oil ... of saturated fat and rich supply of omega-3 fatty acids, ...
Breaking Biology News(10 mins):Tissue regeneration using anti-inflammatory nanomolecules 2Canola genome sequence reveals evolutionary 'love triangle' 2
... Boston, Mass.Researchers at Boston Children,s Hospital have found that ... could potentially protect the fragile lungs of premature babies ... by inflammation. The findings explain earlier research ... called mesenchymal stem cells (MSCs) could help reduce lung ...
... fast. That,s an essential characteristic of what makes them cancer ... continuously growing and dividing, far outstripping our normal cells. To ... CSHL Professor Adrian Krainer and his team have found ... in the process specifically kill cancer cells. Nearly 90 ...
... as regenerating damaged tissues or organs have generated a ... types of applications are exciting, it is a long journey ... cells on human health will most likely come from their ... to generate stem cells by reprogramming cells from patients, skin ...
Cached Biology News:Microscopic packets of stem cell factors could be key to preventing lung disease in babies 2Microscopic packets of stem cell factors could be key to preventing lung disease in babies 3Team uses antisense technology that exploits gene splicing mechanism to kill cancer cells 2Team uses antisense technology that exploits gene splicing mechanism to kill cancer cells 3The role of stem cells in developing new drugs 2
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
... and Tissue Staining Kits are intended for ... of histological and cytological specimens. These kits ... manufactured by either R&D Systems or by ... the formation of the Avidin-Biotin Complex (ABC) ...
... Cellular uptake of long double stranded RNA ... interference in a diverse group of organisms ... RNA interference leads to the inhibition of ... of the target messenger RNA (mRNA). Attempts ...
... is an easy-to-use siRNA transfection reagent that ... genes in a variety of cell lines. ... an optimized, straightforward protocol. High levels of ... following transfection of 20 to 100 nM ...
Biology Products: